NCI-MATCH Trial: Lessons from the Largest Tumour-Agnostic Precision Oncology Study
The NCI-MATCH trial screened nearly 6,000 patients with treatment-refractory solid tumours using next-generation sequencing and assigned 1,593 to one of 38 genomically matched substudies. Seven of the initial 27 substudies (26%) met their signal-seeking objective for tumour response, validating the feasibility of large-scale, tumour-agnostic precision medicine trials. The authors discuss key design and operational lessons for future biomarker-driven platform trials.
The original study
The NCI-MATCH trial: lessons for precision oncology.
- Authors
- O'Dwyer PJ, Gray RJ, Flaherty KT, Chen AP, Li S, Wang V, et al.
- Journal
- Nature medicine
- Type
- Journal Article, Review
- PMID
- 37322121
Original abstract
The NCI-MATCH (Molecular Analysis for Therapy Choice) trial ( NCT02465060 ) was launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial-largely for patients with treatment-refractory, malignant solid tumors. Having completed in 2023, it remains one of the largest tumor-agnostic, precision oncology trials undertaken to date. Nearly 6,000 patients underwent screening and molecular testing, with a total of 1,593 patients (inclusive of continued accrual from standard next-generation sequencing) being assigned to one of 38 substudies. Each substudy was a phase 2 trial of a therapy matched to a genomic alteration, with a primary endpoint of objective tumor response by RECIST criteria. In this Perspective, we summarize the outcomes of the initial 27 substudies in NCI-MATCH, which met its signal-seeking objective with 7/27 positive substudies (25.9%). We discuss key aspects of the design and operational conduct of the trial, highlighting important lessons for future precision medicine studies.